MCKESSON CORP MCK

Industrials SIC 5122 - Wholesale-Drugs, Proprietaries & Druggists' Sundries NAICS Wholesale Trade › Merchant Wholesalers, Nondurable Goods › Drugs and Druggists' Sundries Merchant Wholesalers derived NYSE

McKesson Corporation together with its subsidiaries (collectively, the "Company," "McKesson," "we," "our," or "us" and other similar pronouns), which traces its business roots to 1833, is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.

The Company's fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references in this document to a particular year refer to the Company's fiscal year. The Company was incorporated on July 7, 1994 in the State of Delaware.

Last close 1,000.77 2026-10-23
Market cap $116.68B 2026-06-30 share count
52-week range 723.68 - 1,030.27

Valuation FY2025 figures against the last close

P/S0.3x
P/E26.1x
P/FCF20.4x
EV/EBITDA18.3x
Dividend yield0.3%
Diluted EPS38.38

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $403.43B$359.05B$308.95B$276.71B$263.97B$238.23B$231.05B$214.32B$208.36B$198.53B
Cost of revenue $388.88B$345.73B$296.12B$264.35B$250.84B$226.08B$219.03B$202.56B$197.17B$187.26B
Gross profit $14.55B$13.32B$12.83B$12.36B$13.13B$12.15B$12.02B$11.75B$11.18B$11.27B
R&D ——————$96.0M$71.0M$125.0M$341.0M
SG&A $8.10B$8.51B$8.66B$7.78B$10.54B$8.85B$9.18B$8.44B$8.14B$7.45B
Total operating expenses $8.34B$8.90B$8.92B$7.98B$11.09B$17.19B$9.53B$10.87B$10.42B$4.15B
Operating income $6.21B$4.42B$3.91B$4.38B$2.04B-$5.04B$2.49B$886.0M$762.0M$7.12B
Interest expense $247.0M$265.0M$252.0M$248.0M$178.0M$217.0M$249.0M$264.0M$283.0M—
Pre-tax income $6.20B$4.36B$3.79B$4.63B$1.93B-$5.03B$1.14B$610.0M$239.0M$6.89B
Income tax $1.10B$878.0M$629.0M$905.0M$636.0M$695.0M$18.0M$356.0M$53.0M$1.61B
Net income $4.76B$3.29B$3.00B$3.56B$1.11B-$4.54B$900.0M$34.0M$67.0M$5.07B
EPS, basic 38.5525.8622.5425.237.32-28.264.980.170.3222.95
EPS, diluted 38.3825.7222.3925.037.23-28.264.950.170.3222.73
Shares, diluted (wtd. avg.) 124.1M128.1M134.1M142.2M154.1M160.6M181.6M197.3M209.0M223.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $3.98B$5.69B$4.58B$4.68B$3.94B$6.40B$4.02B$2.98B$2.67B$4.25B
Receivables $27.98B$25.64B$21.62B$19.41B$18.58B$19.18B$19.95B$18.25B$17.71B$18.21B
Inventory $24.21B$23.00B$21.14B$19.69B$18.70B$19.25B$16.73B$16.71B$16.31B$15.28B
Total current assets $57.21B$55.40B$47.97B$44.29B$46.23B$45.38B$42.22B$38.47B$37.14B$36.95B
Property, plant and equipment $2.67B$2.50B$2.32B$2.18B$2.09B$2.58B$2.37B$2.55B$2.46B$2.29B
Goodwill $11.32B$10.02B$10.13B$9.95B$9.45B$9.49B$9.36B$9.36B$10.92B$10.59B
Other intangibles $4.08B$1.46B$2.11B$2.28B$2.06B$2.88B$3.16B$3.69B$4.10B$3.67B
Total assets $82.32B$75.14B$67.44B$62.32B$63.30B$65.02B$61.25B$59.67B$60.38B$60.97B
Accounts payable $59.97B$55.33B$47.10B$42.49B$38.09B$38.98B$37.20B$33.85B$32.18B$31.02B
Short-term debt ————————$0$183.0M
Total current liabilities $67.02B$61.60B$52.36B$47.96B$48.47B$44.10B$42.62B$37.63B$36.69B$35.61B
Long-term debt $6.53B$5.65B$5.63B$5.59B$5.88B$7.15B$7.39B$7.59B$7.88B$8.36B
Retained earnings $22.29B$17.92B$14.98B$12.29B$9.03B$8.20B$13.02B$12.41B$12.99B$13.19B
Total equity -$2.17B-$2.07B-$1.60B-$1.49B-$1.79B$175.0M$5.31B$8.29B$10.06B$11.27B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $6.16B$6.08B$4.31B$5.16B$4.43B$4.54B$4.37B$4.04B$4.34B$4.74B
Depreciation and amortisation $287.0M$272.0M$279.0M$272.0M$312.0M$344.0M$335.0M$317.0M$303.0M$324.0M
Stock-based compensation ————————$69.0M$115.0M
Capital expenditure $436.0M$537.0M$431.0M$390.0M$388.0M$451.0M$362.0M$426.0M$405.0M$404.0M
Investing cash flow -$3.43B-$733.0M-$1.07B-$542.0M-$89.0M-$415.0M-$579.0M-$1.38B-$2.99B-$3.27B
Financing cash flow -$4.63B-$3.96B-$3.34B-$4.37B-$6.32B-$1.69B-$2.73B-$2.23B-$3.08B-$2.07B
Dividends paid $381.0M$345.0M$314.0M$292.0M$277.0M$276.0M$294.0M$292.0M$262.0M$253.0M
Buybacks $4.75B$3.15B$3.02B$3.64B$3.52B$742.0M$1.93B$1.64B$1.71B$2.31B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000927653-26-000169.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200B 0 200B 400B 600B Revenue, FY2016: 198.5B Gross profit, FY2016: 11.3B Net income, FY2016: 5.1B Revenue, FY2017: 208.4B Gross profit, FY2017: 11.2B Net income, FY2017: 67M Revenue, FY2018: 214.3B Gross profit, FY2018: 11.8B Net income, FY2018: 34M Revenue, FY2019: 231.1B Gross profit, FY2019: 12B Net income, FY2019: 900M Revenue, FY2020: 238.2B Gross profit, FY2020: 12.1B Net income, FY2020: -4.5B Revenue, FY2021: 264B Gross profit, FY2021: 13.1B Net income, FY2021: 1.1B Revenue, FY2022: 276.7B Gross profit, FY2022: 12.4B Net income, FY2022: 3.6B Revenue, FY2023: 309B Gross profit, FY2023: 12.8B Net income, FY2023: 3B Revenue, FY2024: 359.1B Gross profit, FY2024: 13.3B Net income, FY2024: 3.3B Revenue, FY2025: 403.4B Gross profit, FY2025: 14.6B Net income, FY2025: 4.8B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $198.53B $208.36B $214.32B $231.05B $238.23B $263.97B $276.71B $308.95B $359.05B $403.43B
Gross profit $11.27B $11.18B $11.75B $12.02B $12.15B $13.13B $12.36B $12.83B $13.32B $14.55B
Net income $5.07B $67.0M $34.0M $900.0M -$4.54B $1.11B $3.56B $3.00B $3.29B $4.76B

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Material agreement signed Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • New debt or obligation Item 2.03

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 5122

TickerCompanyMarket capP/ERevenue growth
COR Cencora, Inc. $63.16B 41.6x 9.3%
CAH CARDINAL HEALTH INC $58.04B 34.5x 14.2%
HLF HERBALIFE LTD. $1.40B 6.1x 0.9%
NUS NU SKIN ENTERPRISES, INC. $233.2M 1.5x -14.3%
COSM Cosmos Health Inc. $26.3M — 19.9%
HWH HWH International Inc. $20.7M — -30.8%
MEDS DataMeds AI, Inc. $6.8M — 28.7%
HKPD Cellyan Biotechnology Co., Ltd — — —